---
title: "Zepbound Switching: From or To Other GLP-1/GIP Drugs"
description: "A guide to switching between Zepbound (tirzepatide) and other weight-loss medications in the same class, including semaglutide, liraglutide, and oral GLP-1…"
url: https://healthrx.com/zepbound/switching-protocols
publisher: HealthRX.com
---


HealthRX.com

The label sets one Zepbound start for everyone switching

[Print or save as PDF](https://healthrx.com/printables/zepbound/switching-protocols?print=1)

Key numbers

- 2.5 mg Starting dose: once weekly for 4 weeks, same for everyone, including people switching from another GLP-1 Source: [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b), as cited Nov 7, 2026
- 20.2% Weight loss with tirzepatide over 72 weeks in SURMOUNT-5, versus 13.7% with semaglutide Source: [pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/40353578/), as cited Nov 7, 2026
- 4 weeks Backup contraception needed for 4 weeks after starting Zepbound for people using oral hormonal birth control Source: [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b), as cited Nov 7, 2026
- 10.3% Hypoglycemia in type 2 diabetes adults taking a sulfonylurea, versus 2.1% not taking one (SURMOUNT-2) Source: [dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b), as cited Nov 7, 2026

HealthRX.com quick answer. The Zepbound label has one dosing schedule for everyone and no switching protocol: tirzepatide starts at 2.5 mg once weekly for 4 weeks whichever GLP-1 drug a patient is coming from, and the label says coadministration with any GLP-1 receptor agonist, or with another tirzepatide-containing product, is not recommended [1]. The label gives no higher starting dose and no washout interval for someone who was on semaglutide or liraglutide [1].

At a glance

- Drug / Tirzepatide (Zepbound), a dual GIP and GLP-1 receptor agonist given once weekly by subcutaneous injection
- Approved uses / Weight reduction in adults with obesity, or overweight plus a weight-related condition; moderate-to-severe obstructive sleep apnea in adults with obesity [1]
- Label on combining / Coadministration with any GLP-1 receptor agonist or another tirzepatide product is not recommended [1]
- Washout or cross-taper in the label / None described
- First dose after a switch / 2.5 mg once weekly for 4 weeks, then 5 mg [1]
- Maintenance and maximum / 5, 10 or 15 mg weekly; maximum 15 mg [1]
- Half-life / About 5 days, with steady state after 4 weeks of weekly dosing [1]
- Head-to-head weight data / SURMOUNT-5: -20.2% with tirzepatide vs -13.7% with semaglutide at 72 weeks [2]

## What the Zepbound label says about switching

The limitation of use is the closest the prescribing information comes to the question: Zepbound contains tirzepatide, and coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended [1]. The dosing section sets one schedule for every patient, with no separate instructions for someone arriving from another incretin [1].

The 2.5 mg [starting dose](https://healthrx.com/zepbound/adult-dosing) is for initiation only and is not approved as a maintenance dose [1]. Maintenance for weight reduction is 5, 10 or 15 mg once weekly, and for obstructive sleep apnea it is 10 or 15 mg, with a maximum of 15 mg for all indications [1]. If a maintenance dose is not tolerated, the label says to consider a lower maintenance dose [1].

## Is a washout period needed between GLP-1 drugs?

The Zepbound label gives no washout interval for switching from another GLP-1 drug [1].

What the label does settle is that the two drugs are not meant to run together [1]. Tirzepatide has a [half-life](https://healthrx.com/zepbound/pharmacokinetics) of about 5 days and reaches steady state after 4 weeks of once-weekly dosing [1].

## Starting dose after another GLP-1 drug

The label gives no milligram-for-milligram conversion. SURMOUNT-5 compared maximum tolerated doses, tirzepatide 10 or 15 mg against semaglutide 1.7 or 2.4 mg, not equivalent doses [2]. The label's schedule is 2.5 mg once weekly for 4 weeks, then 5 mg, with 2.5 mg increases allowed after at least 4 weeks on the current dose [1].

In SURMOUNT-5, 751 adults with obesity and without [type 2 diabetes](https://healthrx.com/conditions-type-2-diabetes/diagnosis-algorithm) took the maximum tolerated dose of tirzepatide or semaglutide for 72 weeks; weight fell 20.2% with tirzepatide and 13.7% with semaglutide, and waist circumference fell 18.4 cm versus 13.0 cm [2].

In type 2 diabetes, SURPASS-2 randomized 1,879 adults on [metformin](https://healthrx.com/metformin/switching-protocols) to [tirzepatide](https://healthrx.com/products/tirzepatide) 5, 10 or 15 mg or semaglutide 1 mg for 40 weeks; HbA1c fell 2.01, 2.24 and 2.30 points with tirzepatide versus 1.86 with semaglutide, and weight fell 7.6, 9.3 and 11.2 kg versus 5.7 kg [3].

What people on Reddit report

Accounts from people moving from Zepbound to oral GLP-1 drugs such as Foundayo or the Wegovy pill, with mixed weight results.

CBinCHS · Zepbound

Didn't work for me. The guidance now is to start Foundayo at the starter dose - I gained six pounds in a month. Went back to Tirz.

Reports weight gain after starting Foundayo at the starter dose, then went back to tirzepatide.

[Read the source discussion](https://www.reddit.com/r/Zepbound/comments/1x3fntc/switching_from_zepbound_to_an_oral_glp1/)

cpots007 · Zepbound

Since I've been paying OOP this whole time, I talked to my Dr. about Foundayo and with her agreement I switched to 2.5 with Foundayo. Only been on it a month but no issues and zero weight gain and thoroughly enjoying the lower price.

Switched from Zepbound to Foundayo with a doctor's agreement and reports no weight gain so far.

[Read the source discussion](https://www.reddit.com/r/Zepbound/comments/1x3fntc/switching_from_zepbound_to_an_oral_glp1/)

cpots007 · Zepbound

I was worried about having to start at minimum but apparently Lilly provides Dr.'s with a suggested Foundayo dosage based on your current Zepbound dosage, which is 2.5. So far, it feels like the 2.5 is working just fine!

Says the suggested Foundayo dose was based on the current Zepbound dose and is working so far.

[Read the source discussion](https://www.reddit.com/r/Zepbound/comments/1x3fntc/switching_from_zepbound_to_an_oral_glp1/)

Questions worth asking

Choose the questions you want to keep Will my prescriber start me at the lowest dose when switching from Zepbound? Is there a guideline for the first dose of another GLP-1 drug after Zepbound? Should I space my doses differently during the switch and for how long? Can my current Zepbound dose be used to set the dose of the new medicine? How should I track weight and side effects during the first month after switching? Which of my other medicines need monitoring during a switch, such as warfarin?

## Oral contraceptives and other oral medicines during a switch

The label says delayed gastric emptying may reduce the efficacy of oral hormonal contraceptives, and advises patients using them to switch to a non-oral method or add a barrier method for 4 weeks after starting Zepbound and for 4 weeks after each dose escalation; hormonal methods that are not taken orally should not be affected [1]. In a pharmacokinetic study with a single 5 mg tirzepatide dose and a combined pill containing 0.035 mg ethinyl estradiol and 0.25 mg norgestimate, peak levels of ethinyl estradiol, norgestimate and norelgestromin fell 59%, 66% and 55%, total exposure fell 20%, 21% and 23%, and time to peak was delayed by 2.5 to 4.5 hours [1].

Gastric emptying also affects other oral drugs. The label says to monitor medicines that depend on threshold concentrations and those with a narrow therapeutic index, such as warfarin [1]. After a first 5 mg dose, acetaminophen peak concentration fell 55% and peaked 1 hour later; by week 6 on 15 mg there was no meaningful effect on peak concentration or time to peak, and total exposure was unchanged [1].

## Hypoglycemia risk when switching with insulin or sulfonylureas

Zepbound lowers blood glucose, and the label advises considering a lower dose of insulin or an insulin secretagogue such as a sulfonylurea when starting, to reduce hypoglycemia risk [1]. In SURMOUNT-2, which enrolled adults with type 2 diabetes, hypoglycemia with glucose below 54 mg/dL occurred in 10.3% of patients taking a sulfonylurea versus 2.1% of those not taking one [1].

## Before the first dose

Zepbound is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in those with a known serious hypersensitivity to tirzepatide or any excipient [1]. The boxed warning describes thyroid C-cell tumors in rats at clinically relevant exposures, states that human relevance is unknown, and notes that routine calcitonin monitoring or thyroid ultrasound is of uncertain value [1].

The label says Zepbound is not recommended in patients with severe gastroparesis, and severe gastrointestinal reactions were reported in 1.7% of patients on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg versus 1% on placebo [1]. If pancreatitis is suspected, the label says to discontinue Zepbound [1]. On [pregnancy](https://healthrx.com/zepbound/pregnancy-lactation), the label states that weight loss offers no benefit and may cause fetal harm, and says to discontinue Zepbound when pregnancy is recognized [1].

## What the titration weeks look like

In the pooled weight-management trials behind the label, nausea occurred in 25%, 29% and 28% of patients on 5, 10 and 15 mg versus 8% on placebo, and most nausea, vomiting and diarrhea happened during dose escalation and decreased over time [1]. Treatment was permanently discontinued for adverse reactions in 4.8%, 6.3% and 6.7% of patients on 5, 10 and 15 mg versus 3.4% on placebo [1].

## Leaving Zepbound: what happens to weight

Stopping tirzepatide was followed by substantial weight regain in SURMOUNT-4 [4]. In that trial, 783 adults entered a 36-week open-label tirzepatide lead-in [4]. The 670 who were then randomized had lost a mean 20.9% of their body weight; from week 36 to week 88, weight changed -5.5% in those who continued tirzepatide versus +14.0% in those switched to placebo [4].

SURMOUNT-5 assigned adults to tirzepatide or semaglutide for 72 weeks, and those assigned to semaglutide lost less weight on average [2]. It did not test switching from one drug to the other [2].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the label, what is the Zepbound starting dose given once weekly for the first 4 weeks?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Try the tool

Tirzepatide dose calculator and dosage chart

Convert a tirzepatide dose between mg, mL and U-100 syringe units, with the 2.5 to 15 mg label chart.

[Open the dose calculator](https://healthrx.com/tools/tirzepatide-dose-calculator)

Printable question sheet

Zepbound switching visit sheet for prescriber or pharmacist

Use this sheet before a visit about moving to or from Zepbound (tirzepatide) or another weight or diabetes injection such as semaglutide. Fill it in by hand, bring it to your prescriber or pharmacist, and keep a copy.

[Open the fill-in sheet](https://healthrx.com/printables/zepbound/switching-protocols) Fill it in, print it or save it as a PDF. No sign-up.

Victoza fading after its last dose while Zepbound builds up

Switch from liraglutide (Victoza, daily injection) to tirzepatide (Zepbound, weekly injection)

liraglutide (Victoza, daily injection) tirzepatide (Zepbound, weekly injection) a dose

Week 7 of 7

**liraglutide (Victoza, daily injection):** 0% of its steady-state peak at the end of week 7; highest that week 0%. **tirzepatide (Zepbound, weekly injection):** 79% of its steady-state peak at the end of week 7; highest that week 100%.

Victoza has a label half-life of approximately 13 hours, so its line drops quickly once the once daily doses stop, with a label peak at 8 to 12 hours after a dose. Zepbound has a half-life of approximately 5-6 days and a median time to peak of 24 hours, so its once weekly line climbs gradually, and the label says steady state comes after 4 weeks of once weekly dosing. The two lines overlap only briefly, and each is scaled to its own peak, so the height of one line says nothing about the other.

Label figures this curve uses

| Victoza half-life | approximately 13 hours |
| --- | --- |
| Victoza time to peak | 8 to 12 hours (Midpoint of 10 hours used for the curve) |
| Victoza dosing interval | once daily |
| Zepbound half-life | approximately 5-6 days (Midpoint of 5.5 days used for the curve) |
| Zepbound time to peak | 24 hours (8 to 72 hours) (Median and range) |
| Zepbound dosing interval | once weekly |

Week by week numbers

Percent of the steady-state peak

| Week | liraglutide (Victoza, daily injection): highest, then end of week | tirzepatide (Zepbound, weekly injection): highest, then end of week |
| --- | --- | --- |
| 1 | 99%, 1% | 57%, 46% |
| 2 | 1%, 0% | 82%, 66% |
| 3 | 0%, 0% | 93%, 73% |
| 4 | 0%, 0% | 97%, 77% |
| 5 | 0%, 0% | 99%, 78% |
| 6 | 0%, 0% | 99%, 79% |
| 7 | 0%, 0% | 100%, 79% |

Source: [Victoza prescribing information, DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4), section 12.3 Pharmacokinetics, Oct 14, 2025; [Zepbound prescribing information, DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b), section 12.3 Pharmacokinetics, Aug 28, 2026

Drawn with a one-compartment model and equal doses. It shows the pattern the label figures imply, as a percent of the steady-state peak, not anyone's measured level.

For education only. This tool shows what the cited sources say; it does not diagnose anything or set a dose. Talk with your clinician before you change how you take a medicine.

Frequently asked questions

Do I need to wait a week between my last Wegovy shot and my first Zepbound shot?

The Zepbound label gives no specific waiting interval and does not recommend taking it alongside another GLP-1 drug [1].

Should the starting dose be higher if I was on semaglutide 2.4 mg for years?

The label has one starting dose for all indications: 2.5 mg once weekly for 4 weeks, then 5 mg, with increases of 2.5 mg no sooner than every 4 weeks [1]. The 2.5 mg dose is for initiation and is not approved as a maintenance dose [1].

Can Zepbound and semaglutide be taken together during a transition?

The Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended [1].

Is there a dose of Zepbound that equals a dose of Wegovy?

No conversion is given. SURMOUNT-5 compared maximum tolerated doses, tirzepatide 10 or 15 mg against semaglutide 1.7 or 2.4 mg, rather than equivalent milligrams [2], and the Zepbound label contains no cross-drug dose table [1].

Does starting Zepbound affect birth control pills?

The label says use may reduce the efficacy of oral hormonal contraceptives and advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose escalation; non-oral hormonal methods should not be affected [1].

What happens to weight if Zepbound is stopped?

In SURMOUNT-4, weight changed -5.5% from week 36 to week 88 in people who continued tirzepatide and +14.0% in those switched to placebo, after a mean 20.9% reduction during a 36-week lead-in [4].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Is it okay to switch from Ozempic to Zepbound?

No switching protocol is given. The Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended, so the two drugs should not be taken together. The label sets no washout interval and no higher starting dose for patients coming from semaglutide: everyone starts at 2.5 mg once weekly for 4 weeks, then 5 mg.

What are the key differences between semaglutide and tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist given once weekly. In SURMOUNT-5, adults who took the maximum tolerated dose for 72 weeks lost 20.2% of body weight with tirzepatide versus 13.7% with semaglutide. Tirzepatide has a half-life of about 5 days and reaches steady state after 4 weeks of once-weekly dosing.

References

Show all 5 references Hide references

1. U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. [Zepbound injection (tirzepatide) label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)
2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. [Tirzepatide as Compared with Semaglutide for the Treatment of Obesity](https://pubmed.ncbi.nlm.nih.gov/40353578/). N Engl J Med. 2025;393(1):26-36.
3. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. [Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes](https://pubmed.ncbi.nlm.nih.gov/34170647/). N Engl J Med. 2021;385(6):503-515.
4. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. [Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial](https://pubmed.ncbi.nlm.nih.gov/38078870/). JAMA. 2024;331(1):38-48.
5. Reddit participants. [Switching from Zepbound to an oral GLP-1? (r/Zepbound)](https://www.reddit.com/r/Zepbound/comments/1x3fntc/switching_from_zepbound_to_an_oral_glp1/). Accessed 2026-11-10.

Next in this cluster

Related reading

- [tirzepatide Zepbound switching](https://healthrx.com/reviews-zepbound/switching-reports)
- [tirzepatide Zepbound real-world evidence](https://healthrx.com/zepbound/real-world-evidence)
- [tirzepatide How Long Has Zepbound Been Around? FDA History Explained](https://healthrx.com/zepbound/history-development)
- [tirzepatide Zepbound older adult safety](https://healthrx.com/zepbound/older-adult-safety)
- [tirzepatide Zepbound Adult (30-49) Dosing](https://healthrx.com/zepbound/adult-dosing)
- [tirzepatide Zepbound adult monitoring](https://healthrx.com/zepbound/adult-monitoring)
- [tirzepatide Zepbound Travel & Timezone-Shift Protocols](https://healthrx.com/zepbound/travel-protocols)
- [tirzepatide Zepbound TRICARE prior authorization](https://healthrx.com/zepbound/tricare-coverage)
- [tirzepatide Does UnitedHealthcare cover Zepbound](https://healthrx.com/zepbound/unitedhealthcare-coverage)
- [tirzepatide Zepbound young adult dosing](https://healthrx.com/zepbound/young-adult-dosing)
- [tirzepatide Zepbound young adult monitoring](https://healthrx.com/zepbound/young-adult-monitoring)
- [tirzepatide Tirzepatide young adult safety](https://healthrx.com/zepbound/young-adult-safety)
- [tirzepatide Zepbound for diabetes](https://healthrx.com/off-label-zepbound/diabetes--dosing-protocol)
- [side effects zepbound nausea When Nausea on Zepbound (tirzepatide) Becomes a Reason to Stop](https://healthrx.com/side-effects-zepbound-nausea/when-to-stop)

![Zepbound switching: man planning a medication transition during a telehealth video visit at home](https://zwulxpn434zaufgz.public.blob.vercel-storage.com/page-images/zepbound/switching-protocols.webp)

Planning a switch between weight-loss medications with a clinician by video helps ensure the timing and starting dose are right. Full Zepbound switching guide and sources at [healthrx.com/zepbound](https://healthrx.com/zepbound).
